cd5-car-γδ t cells

**CD5-CAR-γδ T cells** are a form of chimeric antigen receptor (CAR)-engineered cell therapy in which human γδ T cells are genetically modified to express a CAR targeting the CD5 antigen. CD5 is a cell surface molecule highly expressed on malignant T cells, especially in T-cell acute lymphoblastic leukemia (T-ALL) and certain lymphomas. - γδ T cells are selected to reduce the risk of graft-versus-host disease compared to traditional αβ T cell-based CAR therapies, making them attractive for allogeneic "off-the-shelf" use[2][4]. - To prevent fratricide (where engineered T cells kill each other due to shared CD5 expression), the CD5 gene is knocked out using gene editing (such as CRISPR/Cas9), yielding fratricide-resistant CAR-γδ T cells[1][2][3]. - Engineering often uses nanobody (VHH)-based targeting domains and mRNA or viral vector delivery[2]. - Mechanistically, these cells combine MHC-independent innate cytotoxicity of γδ T cells with antigen-specific targeting through the engineered CAR, as well as enhanced anti-tumor activity from the disruption of the inhibitory CD5 signaling pathway[1][2][3]. - These products are investigated for the treatment of T cell malignancies—primarily T-ALL—and may have broader applications in both hematological and solid tumors due to increased proliferation, survival, and tumoricidal activity[1][2][3][4]. - Main developers are academic/research institutions.

Other names

CD5-CAR-gamma delta T cellsCD-5-CAR-gamma delta T cellsCD 5-CAR-gamma delta T cellsCD5-CAR-γδTCD5- cellsCD5-NSCAR-γδ T cells